Literature DB >> 6357964

Effects of tripotassium dicitrato bismuthate (TDB) tablets or cimetidine in the treatment of duodenal ulcer.

I Hamilton, B W Worsley, H J O'Connor, A T Axon.   

Abstract

Forty patients with duodenal ulcer were randomly allocated to treatment with either tripotassium dicitrato bismuthate tablets or cimetidine for six weeks. Endoscopically confirmed healing of the ulcer occurred in 80% treated with tripotassium dicitrato bismuthate tablets and in 85% treated with cimetidine. Symptomatic improvement was also similar in the two groups. Treatment with cimetidine was associated with an increase in pH of gastric aspirate during treatment and increased numbers of bacteria were isolated from the gastric aspirate during treatment, while the pH and bacterial flora of gastric aspirate did not change during tripotassium dicitrato bismuthate treatment. Serum and urinary bismuth levels rose during treatment with tripotassium dicitrato bismuthate and urinary excretion remained raised two weeks after cessation of treatment. Tripotassium dicitrato bismuthate tablets appear to be as effective as cimetidine in the treatment of duodenal ulcer without the potentially undesirable effects of a reduction in gastric acid secretion.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6357964      PMCID: PMC1420250          DOI: 10.1136/gut.24.12.1148

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  10 in total

1.  Studies on the intestinal flora. I. The bacterial flora of the gastrointestinal tract in healthy and achlorhydric persons.

Authors:  B S Drasar; M Shiner; G M McLeod
Journal:  Gastroenterology       Date:  1969-01       Impact factor: 22.682

2.  Effect of cimetidine on the gastric bacterial flora.

Authors:  W S Ruddell; A T Axon; J M Findlay; B A Bartholomew; M J Hill
Journal:  Lancet       Date:  1980-03-29       Impact factor: 79.321

3.  Controlled trial comparing De-Nol tablets with De-Nol liquid in treatment of duodenal ulcer.

Authors:  I Hamilton; A T Axon
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-31

4.  Pathogenesis of gastric cancer in pernicious anaemia.

Authors:  W S Ruddell; E S Bone; M J Hill; C L Walters
Journal:  Lancet       Date:  1978-03-11       Impact factor: 79.321

5.  Intragastric acidity, bacteria, nitrite, and N-nitroso compounds before, during, and after cimetidine treatment.

Authors:  G J Milton-Thompson; N F Lightfoot; Z Ahmet; R H Hunt; J Barnard; P M Bavin; R W Brimblecombe; D W Darkin; P J Moore; N Viney
Journal:  Lancet       Date:  1982-05-15       Impact factor: 79.321

6.  Cimetidine is unlikely to increase formation of intragastric N-nitroso-compounds in patients taking a normal diet.

Authors:  T J Muscroft; D J Youngs; D W Burdon; M R Keighley
Journal:  Lancet       Date:  1981-02-21       Impact factor: 79.321

7.  Randomised open controlled trial of colloidal bismuth subcitrate tablets and cimetidine in the treatment of duodenal ulcer.

Authors:  G Vantrappen; P Rutgeerts; L Broeckaert; J Janssens
Journal:  Gut       Date:  1980-04       Impact factor: 23.059

8.  Simultaneous culture of saliva and jejunal aspirate in the investigation of small bowel bacterial overgrowth.

Authors:  I Hamilton; B W Worsley; I Cobden; E M Cooke; J G Shoesmith; A T Axon
Journal:  Gut       Date:  1982-10       Impact factor: 23.059

9.  Difference in relapse rates of duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuthate.

Authors:  D F Martin; D Hollanders; S J May; M M Ravenscroft; D E Tweedle; J P Miller
Journal:  Lancet       Date:  1981-01-03       Impact factor: 79.321

10.  Cimetidine in the treatment of active duodenal and prepyloric ulcers.

Authors:  G Bodemar; A Walan
Journal:  Lancet       Date:  1976-07-24       Impact factor: 79.321

  10 in total
  18 in total

1.  Anomalous short plasma elimination half life in a patient intoxicated with bismuth subcitrate.

Authors:  A J McLean; S Islam; J R Lambert
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

3.  Effect of nizatidine 300 mg at night and omeprazole 20 mg in the morning on 24-hour intragastric pH and bacterial overgrowth in patients with acute duodenal ulcer.

Authors:  R J Brummer; R W Stockbrügger
Journal:  Dig Dis Sci       Date:  1996-10       Impact factor: 3.199

4.  Relapse of duodenal ulcer: does it matter which drug is used in initial treatment?

Authors:  J P Miller; E B Faragher
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-01

5.  Binding of bismuth to cell components: clue to mode of action and side effects.

Authors:  M Locke; H Nichol; C Ketola-Pirie
Journal:  CMAJ       Date:  1987-12-01       Impact factor: 8.262

6.  Binding of bismuth to cell components: clue to mode of action and side effects.

Authors:  J S Benyon; J de Wal
Journal:  CMAJ       Date:  1988-06-15       Impact factor: 8.262

7.  Epidermal growth factor (EGF) in the gastroprotective and ulcer healing actions of colloidal bismuth subcitrate (De-Nol) in rats.

Authors:  S J Konturek; A Dembinski; Z Warzecha; W Bielanski; T Brzozowski; D Drozdowicz
Journal:  Gut       Date:  1988-07       Impact factor: 23.059

8.  The pathophysiology of peptic ulcer disease.

Authors:  F P Brooks
Journal:  Dig Dis Sci       Date:  1985-11       Impact factor: 3.199

9.  Uptake and subcellular localisation of bismuth in the gastrointestinal mucosa of rats after short term administration of colloidal bismuth subcitrate.

Authors:  D Stiel; D J Murray; T J Peters
Journal:  Gut       Date:  1985-04       Impact factor: 23.059

10.  Duodenal bacterial overgrowth during treatment in outpatients with omeprazole.

Authors:  M Fried; H Siegrist; R Frei; F Froehlich; P Duroux; J Thorens; A Blum; J Bille; J J Gonvers; K Gyr
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.